BFRI BIOFRONTERA INC

BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON WEDNESDAY, NOVEMBER 30, MONDAY, DECEMBER 5, FRIDAY, DECEMBER 9, AND MONDAY, DECEMBER 19 2022

BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON WEDNESDAY, NOVEMBER 30, MONDAY, DECEMBER 5, FRIDAY, DECEMBER 9, AND MONDAY, DECEMBER 19 2022

Woburn, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. ("Biofrontera" or the "Company") (NASDAQ: BFRI), announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Wednesday, November 30, 2022, at 12:00 PM EST, Monday, December 5, 2022, at 1:00 PM CST, Friday, December 9, 2022 at 12:00 PM EST and Monday, December 19, 2022 at 1:00 PM PST. Biofrontera Inc. welcomes stakeholders, investors, and other individual followers to register and attend these live events.

The presentation will feature Prof. Hermann Luebbert, Executive Chairman, Erica Monaco, CEO, and Fred Leffler, CFO. Topics to be covered will include the investor presentation including the latest company news, followed by a live Q&A. Investors interested in participating in this event will need to register using the link below. As a reminder, registration for the live event may be limited, but access to the replay after the event will be on the company’s investor page.

REGISTER HERE:

Wednesday, November 30, 2022:

Monday, December 5, 2022:

Friday, December 9, 2022:

Monday, December 19, 2022:

  • To ensure smooth connectivity, please access this link using the latest version of Google Chrome.

About Biofrontera Inc.

Biofrontera is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. Biofrontera, Inc. was founded in March 2015 to commercialize the FDA-approved flagship drug Ameluz® (aminolevulinic acid hydrochloride) gel, 10%, in the United States. In 2019, Biofrontera Inc. expanded its U.S.-product portfolio with the FDA-approved drug Xepi® (ozenoxacin) cream, 1%. With both FDA-approved products, Biofrontera Inc. is ideally positioned for sustainable growth.

About Renmark Financial Communications Inc.

Founded in 1999, Renmark Financial Communications Inc. is North America’s leading retail investor relations firm. Employing a strategic and comprehensive mix of exposure tactics; Renmark hosts Virtual Non-Deal Roadshows as well as in-person corporate presentations and maintains daily communications with thousands of brokers and money managers across Canada and the United States. Renmark empowers its publicly traded clientele to maximize their visibility within the financial community and strengthen their investor audience.

CONTACT:

Renmark Financial Communications Inc.

Robert Thaemlitz:

Tel.: (416) 644-2020 or (212) 812-7680



EN
28/11/2022

Underlying

BFRIBIOFRONTERA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOFRONTERA INC

 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

U.S. Patent Office Issues Final Written Decision Finding All Challenge...

U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”), today announced that on February 23, 2026, the U.S. Patent Trial and Appeal Board (the “Board”) issued a Final Written Decision finding all challenged claims of Sun Pharmaceutical Industries, Inc.’s U.S. Patent No. 11,697,028 (the “’028 Patent”) to be unpatentable. ...

23h / 23m 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics S...

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities Phase 1 maximal-use pharmacokinetics (PK) study completed in support of planned U.S. label expansionData to complement previously announced positive Phase 3 efficacy results on extremities, neck and trunkSupplemental NDA submission for extremities, neck and trunk indication expected in Q3 2026 WOBURN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the dev...

February 17, 2026 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug A...

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026If approved, Ameluz® would be the first and only PDT photosensitizer indicated for the treatment of superficial Basal Cell Carcinoma (sBCC) in the USBCC is the most common skin cancer in the US with 3.6 million cases diagnosed annually1 WOBURN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical compa...

February 11, 2026 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT...

Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint Study findings met its primary endpoint and showed highly statistically significant superiority for Ameluz® vs. vehicle gel (p

February 9, 2026 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Reve...

Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth Fourth quarter results represent highest quarterly revenue in Company’s historyQ4 year-over-year growth of 35% to 39% driven by sales execution of Ameluz®Full year 2025 revenues also expected to show double-digit growth of 11% to 13% WOBURN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a leader in photodynamic therapy (PDT) development and commercialization, to...

January 13, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch